A Study to Assess the Effect Probiotic Supplement on Immune Health in Teachers Prone to Upper Respiratory Tract Infection
NCT ID: NCT07033754
Last Updated: 2025-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
100 participants
INTERVENTIONAL
2025-06-25
2026-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of a Probiotic on Upper Respiratory Tract Infections
NCT03636191
A Study to Assess the Effect of a Probiotic on Upper Respiratory Tract Infections in Healthy Children
NCT05577065
The Effect of a Probiotic on Protection Against Upper Respiratory Tract Infections in Children
NCT01935986
A Study to Investigate the Effect of Probiotics (L. Reuteri ATCC PTA 5289 and L. Reuteri DSM 17938) on Symptoms of Viral Upper Respiratory Tract Infections in Children
NCT06205966
Evaluation of Probiotics on Symptoms of Upper Respiratory Tract Infections
NCT00599430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propionibacterium freudenreichii P.UF1
one capsule once a day with/beforebreakfast for 120 days
Propionibacterium freudenreichii P.UF1
one capsule once a day with/beforebreakfast for 120 days
Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia
one capsule once a day with/beforebreakfast for 120 days
Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia
one capsule once a day with/beforebreakfast for 120 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propionibacterium freudenreichii P.UF1
one capsule once a day with/beforebreakfast for 120 days
Microcrystalline cellulose, calciumcarbonate, Mg Stearate, Sylysia
one capsule once a day with/beforebreakfast for 120 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male and female teachers aged between 18 to 50 years' (both values included) withmoderate physical activity level as per International Physical Activity Questionnaire -Short Form (IPAQ - SF).
3. Individuals with body mass index (BMI) between 22 kg per m2 to 32.0 kg per m2
4. High susceptibility to URTIs at least once every three months for last 1 year (at least 4to 6 episodes in a year).
5. Individuals who have active URTI episode at screening defined as "those having a scoreof less than equal to 5 for at least 2 symptoms out of runny nose, plugged nose,sneezing, sore throat, scratchy throat, cough or head congestion on the WURSS-21".
6. Commitment to adhere to routine diet and physical activity.
7. Willing to discontinue any immune-enhancing dietary supplements (e.g., prebiotics andfiber supplements, probiotics, Echinacea, fish oil, vitamin E, etc.) at least 1 one monthprior to screening.
8. Willing to discontinue sleep medications at least 1 month prior to screening and duringthe entire study duration.
9. Individuals willing to complete all study-related and clinical study visits as per theprotocol.
Exclusion Criteria
2. Individuals taking prebiotics, probiotics, synbiotics or post-biotics supplements 1 monthprior to screening.
3. Individuals with known sensitivity to the investigational products or any excipients ofthe product.
4. Individuals with any clinically significant abnormalities of the upper respiratory tract(such as stridor, laryngomalacia, etc.).
5. Individuals suffering from lower respiratory tract infection (LRTI) of any origin.
6. Any individual not willing to follow the abstinence from any home-based remedies for common cold such as steam inhalation, decoctions, and vapor rub, etc.
7. Individuals with uncontrolled type 2 diabetes as assessed by fasting blood glucose lessthan equal to 126 mg per dL.
8. Individuals with uncontrolled hypertension on medication and with systolic bloodpressure less than 140 and or diastolic blood pressure less than equal to 90 mmHg.
9. Individuals who are unable to abstain from herbal or dietary supplements for URTI throughout the study period.
10. Vaccination against influenza or swine flu within 90 days prior to screening.
11. Those who have taken or should be taking or are taking antibiotics, antivirals, steroids,nasal decongestants, antihistamines, NSAIDs, or other medications that are expected to alleviate cold symptoms within two weeks prior to screening.
12. History of any significant neurological and psychiatric condition which may affect theparticipation and inference of the study's end points.
13. Participation in other clinical trials in last 90 days prior to screening
14. Individuals with substance abuse problems (within 2 years) defined as: a) Use ofrecreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/Nicotine, tobaccoor smoking dependence. b) High-risk drinking as defined by consumption of 4 or morealcohol containing beverages on any day or 8 or more alcohol containing beverages perweek for women and 5 or more alcohol-containing beverages on any day or 15 or morealcohol containing beverages per week for men.
15. Individuals who have clinically significant following severe illness
16. Females who are pregnant/planning to be pregnant or lactating or taking any oralcontraceptives.
17. Any condition that could, in the opinion of the investigator, preclude the individual'sability to successfully and safely complete the study or that may confound studyoutcomes
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nand Hospital
Vadodara, Gujarat, India
Lifeline Clinicand Diagnostics
Nashik, Maharashtra, India
AMF MorayaMultispecialityHospital
Pune, Maharashtra, India
ENT and VertigoClinic
Pune, Maharashtra, India
Madhumeh Clinic
New Delhi, National Capital Territory of Delhi, India
Janta Hospital &MaternityCentre
Varanasi, Uttar Pradesh, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SB/240701/IP/URTI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.